AD | MedChemExpress (MCE) Life Science Reagents

By Targets:	11β-HSD (2) 5-HT Receptor (9) Adrenergic Receptor (4) AMPK (1) Amyloid-β (43) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (3) Apoptosis (13) Autophagy (5) Bacterial (5) Bcl-2 Family (1) Beta-secretase (15) Biochemical Assay Reagents (3) Calcium Channel (2) Carbonic Anhydrase (3) Casein Kinase (1) Caspase (1) CCR (1) CDK (4) Chemerin Receptor (1) Cholinesterase (ChE) (72) Complement System (2) COX (1) Cytochrome P450 (1) Dopamine Receptor (4) Dopamine Transporter (3) Drug Metabolite (2) DYRK (1) E1/E2/E3 Enzyme (2) EBV (1) EGFR (1) Endogenous Metabolite (12) Ephrin Receptor (1) ERK (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (3) Fluorescent Dye (2) Glucocorticoid Receptor (3) GLUT (1) GSK-3 (8) HBV (1) HDAC (2) Histamine Receptor (7) Histone Methyltransferase (1) HIV (1) HPV (1) HSP (1) iGluR (1) Interleukin Related (7) IRAK (1) Isotope-Labeled Compounds (19) JNK (3) Keap1-Nrf2 (3) mAChR (3) MAGL (1) MicroRNA (9) Microtubule/Tubulin (5) Mitochondrial Metabolism (2) MMP (1) Molecular Glues (1) Monoamine Oxidase (14) mTOR (1) nAChR (5) Neuropeptide Y Receptor (2) NF-κB (6) NO Synthase (1) NOD-like Receptor (NLR) (2) Nuclear Factor of activated T Cells (NFAT) (1) Oxidative Phosphorylation (2) P-glycoprotein (3) p38 MAPK (1) p62 (2) Parasite (2) Phosphatase (2) Phosphodiesterase (PDE) (6) Phospholipase (3) PI3K (1) PKC (1) PPAR (3) Prostaglandin Receptor (1) PROTACs (2) Proteasome (2) Raf (3) Reactive Oxygen Species (1) RET (5) Ribosomal S6 Kinase (RSK) (3) RIP kinase (1) Sigma Receptor (3) Sodium Channel (1) Src (3) Tau Protein (9) TNF Receptor (1) Trk Receptor (1) Wnt (2) α-synuclein (2) β-catenin (2) γ-secretase (7)
By Research Areas:	Cancer (34) Cardiovascular Disease (8) Endocrinology (19) Infection (8) Inflammation/Immunology (51) Metabolic Disease (8) Neurological Disease (219)
Click Chemistry:	Alkynes (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161116

AD-5584	Others	Cancer
AD-5584 is an ACSS2 inhibitor with blood-brain permeability. AD-5584 can significantly reduce lipid storage, reduce colony formation, and increase cell death. AD-5584 has antitumor activity .

HY-161117

AD-8007	Others	Cancer
AD-8007 is an acetyl CoA synthase 2 (ACSS2) inhibitor that can cross the blood-brain barrier. AD-8007 can significantly reduce lipid storage and cell colony formation in vitro models, and increase tumor cell death. AD-8007 has anti-cancer activity and can be used in the research of breast cancer .

HY-143886

AD011	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
AD011 is a dual inhibitor of cACE/NEP. AD011 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD011 has the potential for providing the potent antihypertensive and cardioprotective benefits .

HY-143887

AD012	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
AD012 is a dual inhibitor of cACE/NEP. AD012 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD012 has the potential for providing the potent antihypertensive and cardioprotective benefits .

HY-143888

AD013	Angiotensin-converting Enzyme (ACE)	Others
AD013 is a dual inhibitor of cACE/NEP. AD013 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD013 has the potential for providing the potent antihypertensive and cardioprotective benefits .

HY-U00005

AD 0261	Reactive Oxygen Species	Inflammation/Immunology
AD 0261 is a radical scavenger which displays strong inhibitory action on the generation of lipid peroxides and superoxide anions.

HY-149428

AD4 1 Publications Verification	PROTACs	Cancer
AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC₅₀: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .

HY-149853

AD186	Sigma Receptor	Neurological Disease
AD186 is a potent and selective S1R agonist with K_is of 2.7, 27 nM for S1R and S2R, respectively. AD186 fully reverses the antiallodynic effect of BD-1063 (HY-18101A) .

HY-W102666

AD-67 MON-4660	Biochemical Assay Reagents	Others
AD-67 (MON-4660) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-118561

Bermoprofen AD-1590	Others	Inflammation/Immunology
Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory agent. Bermoprofen has potent antipyretic activities with a short biological half-life. Bermoprofen is a potent antagonist of LPS-induced fever in rabbits .

HY-18507A

AD57 hydrochloride

RET Src Ribosomal S6 Kinase (RSK) Raf Cancer

AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src .
HY-101963

AD80

Raf Src Ribosomal S6 Kinase (RSK) RET Cancer

AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
HY-18507

AD57

RET Raf Ribosomal S6 Kinase (RSK) Src Cancer

AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity .

AD57 hydrochloride	RET Src Ribosomal S6 Kinase (RSK) Raf	Cancer
AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src .

AD80	Raf Src Ribosomal S6 Kinase (RSK) RET	Cancer
AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.

AD57	RET Raf Ribosomal S6 Kinase (RSK) Src	Cancer
AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity .

HY-13575

Blonanserin AD-5423	5-HT Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor	Neurological Disease
Blonanserin (AD-5423) is a potent and orally active 5-HT_2A (K_i=0.812 nM) and dopamine D2 receptor (K_i=0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension .

HY-B0124

Zonisamide AD 810; CI 912	Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0124A

Zonisamide sodium AD 810 sodium; CI 912 sodium	Carbonic Anhydrase Apoptosis	Cardiovascular Disease Neurological Disease
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-14601

Pioglitazone hydrochloride 20+ Cited Publications U 72107A; AD 4833	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-13772

Valrubicin 1 Publications Verification AD-32	PKC Antibiotic	Inflammation/Immunology Cancer
Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC₅₀s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.

HY-13575A

Blonanserin dihydrochloride AD-5423 dihydrochloride	5-HT Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor	Neurological Disease
Blonanserin dihydrochloride is a potent and orally active 5-HT_2A and dopamine D2 receptor antagonist, with K_i values of 0.812 and 0.142 nM, respectively. Blonanserin dihydrochloride is usually acts as an atypical antipsychotic agent, and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension .

HY-14601R

Pioglitazone hydrochloride (Standard) U 72107A (Standard); AD 4833 (Standard)	PPAR Ferroptosis	Metabolic Disease Cancer
Pioglitazone (hydrochloride) (Standard) is the analytical standard of Pioglitazone (hydrochloride). This product is intended for research and analytical applications. Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-116678

Cloricromen Cloricromene; AD6	Biochemical Assay Reagents	Cardiovascular Disease
Cloricromen (Cloricromene) is a platelet aggregation inhibitor. Cloricromen can inhibit platelet aggregation in man and in experimental thrombosis .

HY-13575S

Blonanserin-d8 AD-5423 d₈	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor	Neurological Disease
Blonanserin-d₈ is a deuterium labeled Blonanserin. Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic[1][2].

HY-13575S1

Blonanserin-d5 AD-5423-d₅	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor	Neurological Disease
Blonanserin-d₅ is a deuterium labeled Blonanserin. Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic[1][2].

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .

HY-105163

Finrozole MPV-2213AD	Cytochrome P450	Endocrinology
Finrozole (MPV-2213ad) is a nonsteroidal, orally active and competitive aromatase enzyme inhibitor. Finrozole can be used for urinary symptoms research .

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), amyloid β aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

HY-R01636

hsa-miR-548ad-3p mimic	MicroRNA	Cancer
hsa-miR-548ad-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-548ad-3p mimic hsa-miR-548ad-3p mimic

HY-R01637

hsa-miR-548ad-5p mimic	MicroRNA	Cancer
hsa-miR-548ad-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-548ad-5p mimic hsa-miR-548ad-5p mimic

HY-RI01636

hsa-miR-548ad-3p inhibitor	MicroRNA
hsa-miR-548ad-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-548ad-3p inhibitor hsa-miR-548ad-3p inhibitor

HY-RI01637

hsa-miR-548ad-5p inhibitor	MicroRNA
hsa-miR-548ad-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-548ad-5p inhibitor hsa-miR-548ad-5p inhibitor

HY-R01636A

hsa-miR-548ad-3p agomir	MicroRNA
hsa-miR-548ad-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-548ad-3p agomir hsa-miR-548ad-3p agomir

HY-R01637A

hsa-miR-548ad-5p agomir	MicroRNA
hsa-miR-548ad-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-548ad-5p agomir hsa-miR-548ad-5p agomir

HY-RI01636A

hsa-miR-548ad-3p antagomir	MicroRNA
hsa-miR-548ad-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-548ad-3p antagomir hsa-miR-548ad-3p antagomir

HY-RI01637A

hsa-miR-548ad-5p antagomir	MicroRNA
hsa-miR-548ad-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-548ad-5p antagomir hsa-miR-548ad-5p antagomir

HY-106000

GSK239512	Histamine Receptor	Neurological Disease
GSK239512 is a potent and brain penetrated H₃ receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) .

HY-162138

BChE-IN-23	Cholinesterase (ChE)	Neurological Disease
BChE-IN-23 (compound 2a) is a BChE inhibitor with an IC₅₀ value of 21 nM. BChE-IN-23 can be used in Alzheimer's disease (AD) research .

HY-14679

GSK3β inhibitor II

GSK-3 Neurological Disease

GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .

GSK3β inhibitor II	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .

HY-109055

Elenbecestat E2609	Beta-secretase	Neurological Disease
Elenbecestat (E2609) is a potent, orally bioavailable and CNS-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research .

HY-P99673

Itepekimab REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-141660

BSc3094

Tau Protein Neurological Disease

BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) .

BSc3094	Tau Protein	Neurological Disease
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) .

HY-114234A

TAK-070 Free base	Beta-secretase	Neurological Disease
TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC₅₀: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model .

HY-162338

BChE-IN-29	Cholinesterase (ChE)	Neurological Disease
BChE-IN-29 (Compound 27a) is a BChE inhibitor (IC₅₀: 0.078 μM and 0.74 μM for BChE and AChE respectively). BChE-IN-29 has anti-inflammatory activity and can be used for research of AD .

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-144753

AChE/BChE-IN-2	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-2 (Compound 13b) is a potent inhibitor of AChE/BChE (AChE IC50 = 0.96 ± 0.14 µM, BChE IC50 = 1.23 ± 0.23 µM). AChE/BChE-IN-2 has the potential for the research of AD diseases .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-151405

Z164597606	Cholinesterase (ChE)	Neurological Disease
Z164597606 is a selective BChE inhibitor (IC₅₀: 1.3 and 1.7 μM for eqBChE and hBChE). Z164597606 forms a π-π stacking interaction with the amino acid Trp82 of hBChE. Z164597606 can be used for the research of Alzheimer’s disease (AD) .

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC₅₀ of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

HY-109085

Difamilast 1 Publications Verification OPA-15406	Phosphodiesterase (PDE)	Inflammation/Immunology
Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC₅₀=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) .

HY-153189

TrkB-IN-1	Trk Receptor	Neurological Disease
TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research .

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library

1366 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1366 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L037

Antioxidant Compound Library

1478 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 1478 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

HY-L028

CNS-Penetrant Compound Library

848 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 848 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L134

Anti-Aging Natural Product Library

193 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L010

MAPK Compound Library

505 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 505 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

HY-L068

Flavonoids Library

512 compounds

Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc.

MCE offers a unique collection of 512 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.

HY-L086

Neurodegenerative Disease-related Compound Library

2221 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2221 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Type

HY-103240

Methoxy-X04	Dyes
Methoxy-X04 is a fluorescent dye that crosses the blood-brain barrier and selectively binds to beta-pleated sheets found in dense core amyloid Aβ plaques. Methoxy-X04 retains in vitro binding affinity for amyloid b (Ab) fibrils (K_i= 26.8 nM). Methoxy-X04 is fluorescent and stains plaques, tangles, and cerebrovascular amyloid in postmortem sections of AD brain with good specificity .

HY-111263

NIAD-4	Fluorescent Dyes/Probes
NIAD-4 is a fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

HY-D2268

QM-FN-SO3	Fluorescent Dyes/Probes
QM-FN-SO₃ is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO₃ can be used for in vivo detection of Aβ plaques. QM-FN-SO₃ has ultra-high S/N ratio, binding affinity, and high-performance NIR emission .

HY-D2268A

QM-FN-SO3 ammonium	Fluorescent Dyes/Probes
QM-FN-SO₃ ammonium is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO₃ ammonium can be used for in vivo detection of Aβ plaques. QM-FN-SO₃ ammonium has ultra-high S/N ratio, binding affinity, and high-performance NIR emission .

Cat. No.	Product Name	Type

HY-W042416

N,N-Dimethylacetamide DMAc	Co-solvents
N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .

HY-W102666

AD-67

MON-4660
Biochemical Assay Reagents

AD-67 (MON-4660) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Target	Research Area

HY-P2284

AD 01	Peptides	Cancer
AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-P1389

Neuropeptide S (human)	Peptides	Neurological Disease
Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research .

HY-P2264

KYL peptide	Ephrin Receptor	Inflammation/Immunology
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC₅₀:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .

HY-P1389A

Neuropeptide S (human) (TFA)	Peptides	Neurological Disease
Neuropeptide S human TFA, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human TFA can be used for Alzheimer's disease (AD) research .

HY-P2712

Chemerin-9, mouse Chemerin148–156, mouse	Chemerin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Chemerin-9, mouse (Chemerin148-156, mouse) is a C-terminal nonapeptide of chemerin. Chemerin-9, mouse is a ligand for ChemR23 (EC₅₀ = 42 nM). Chemerin-9, mouse reduces basal lipolysis in primary mouse white adipocytes(IC₅₀ = 3.3 nM). Chemerin-9, mouse enhances memory and relieves Aβ1-42-induced memory impairment in AD mice. Chemerin-9, mouse also inhibits atherogenesis .

HY-P3781

(Met(O)35)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P2473

Neurogranin (48-76), human	Peptides	Neurological Disease
Neurogranin (48-76), human is a dominant endogenous peptide in Alzheimer's disease (AD) brain tissue. Neurogranin (48-76) is a potential biomarker for synaptic function in AD .

HY-P0198A

Neuropeptide Y (human,rat,mouse) (TFA)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P1046

β-Amyloid (1-15) Amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1466

β-Amyloid (1-16) Amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1468

β-Amyloid (1-28) Amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P2713

OM99-2	Beta-secretase	Neurological Disease
OM99-2, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a K_i value of 9.58 nM . OM99-2 is significantly advanced the development of BACE1 inhibitor . OM99-2 has the potential for the research of the Alzheimer's disease .

HY-P2713A

OM99-2 TFA	Beta-secretase	Neurological Disease
OM99-2 TFA, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a K_i value of 9.58 nM . OM99-2 TFA is significantly advanced the development of BACE1 inhibitor . OM99-2 has the potential for the research of the Alzheimer's disease .

HY-P3528

GPR	Caspase Apoptosis	Neurological Disease
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).

HY-P0198B

[D-Arg25]-Neuropeptide Y (human)	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease
[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y₁ receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity .

HY-122381

Kyotorphin	Bacterial Endogenous Metabolite	Neurological Disease
Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients .

HY-P10037

β Amyloid(17-28) human	Amyloid-β	Neurological Disease
β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD) .

HY-P10039

β Amyloid (1-16) rat	Amyloid-β	Neurological Disease
β-Amyloid (1-16) rat is a β-amyloid peptide (Abeta), a metal-binding domain fragment of amyloid. Three amino acid substitutions in β-Amyloid (1-16) rat that differ from humans render rats and mice less susceptible to AD-like neurodegeneration .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P4899

RE(EDANS)EVNLDAEFK(DABCYL)R	Beta-secretase	Neurological Disease
RE (EDANS) EVNLDAEFK (DABCYL) R is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). RE (EDANS) EVNLDAEFK (DABCYL) R can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction .

HY-P3780

Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .

HY-P1928

Humanin	Bcl-2 Family	Neurological Disease Endocrinology
Humanin, an anti-apoptotic peptide of 24 amino acids, is a Bax inhibitor. Humanin prevents the translocation of Bax from cytosol to mitochondria, blocks Bax from the inactive to active conformation. Humanin is a mitochondria-associated peptide with a neuroprotective effect against AD-related neurotoxicity. Humanin also improves overall insulin sensitivity in animal. Humanin are related to aging . Humanin analogue, in which the serine at position 14 is replaced by glycine, names HNG .

HY-P1383

Rac1 Inhibitor F56, control peptide	Peptides	Others
Rac1 Inhibitor F56, control peptide is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor F56, control peptide contains a Trp ⁵⁶ to Phe ⁵⁶ mutation. Rac1 Inhibitor F56, control peptide has no effect on Rac1 interaction with its guanine nucleotide exchange factors (GEFs) .

HY-P4882

(Pyr3)-Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P4882A

(Pyr3)-Amyloid β-Protein (3-42) (TFA)	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P1387

β-Amyloid (1-40) (rat) 1 Publications Verification	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca ²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .

HY-P0175

740 Y-P 125+ Cited Publications 740YPDGFR; PDGFR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

Cat. No.	Product Name	Target	Research Area

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .

HY-P99673

Itepekimab REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P99163

Tilavonemab ABBV-8E12; C2N-8E12	Microtubule/Tubulin	Neurological Disease
Tilavonemab (ABBV-8E12) is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease .

HY-P99164

Zagotenemab LY33003560	Microtubule/Tubulin	Neurological Disease
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .

HY-P99301

Lokivetmab Anti-Canine IL31 Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Inhibitory Antibodies	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

HY-P99955

Rocatinlimab AMG 451; KHK4083	Inhibitory Antibodies	Infection Inflammation/Immunology
Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .

HY-P99053

Tralokinumab	Interleukin Related	Inflammation/Immunology
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .

HY-P99648

Gosuranemab BMS-986168; IPN007; BIIB092	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .

HY-P99162

Nemolizumab CIM331	Interleukin Related	Inflammation/Immunology
Nemolizumab (CIM331) is a humanized antihuman interleukin-31 receptor A monoclonal antibody that inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD) .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab is a bispecific and humanizedized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0702

Tenuifolin	Triterpenes Structural Classification Terpenoids Source classification Polygalaceae Plants Polygala tenuifolia Willd.	Beta-secretase Cholinesterase (ChE)
Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).

HY-17388

(±)-Huperzine A 1 Publications Verification	Structural Classification Terpenoids Huperziaceae Sesquiterpenes Source classification Huperzia serrata Plants	Cholinesterase (ChE)
(±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).

HY-N2922

β-Amyrin	Structural Classification Monophenols Celastrus hindsii Benth. Celastraceae Phenols Plants	Amyloid-β
β-Amyrin, an ingredient of Celastrus hindsii, blocks amyloid β (Aβ)-induced long-term potentiation (LTP) impairment. β-amyrin is a promising candidate of treatment for AD .

HY-113366

Prostaglandin J2 PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-N10487

Bleformin A	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
Bleformin A is a potent BChE inhibitor with an IC₅₀ value of 5.2 μM. Bleformin A is a nature product that could be isolated from Bletilla striata. Bleformin A can be used for research of Alzheimer's disease (AD) .

HY-N10488

BChE-IN-11	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-N10490

Blestrin D	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-N7887

Cassiaside	Seeds of Cassia tora Linn. other families Leguminosae Source classification Phenols Polyphenols Plants	Beta-secretase
Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against BACE1 (IC₅₀=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity .

HY-N0710

alpha-Cyperone 2 Publications Verification α-Cyperone; (+)-α-Cyperone	other families Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Endogenous metabolite Disease Research Fields Inflammation/Immunology	Endogenous Metabolite
alpha-Cyperone (α-Cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1, resulting in reduction of inflammation, which would be highly beneficial for treatment of inflammatory diseases such as AD.

HY-N144114

P-gp inhibitor 2	Classification of Application Fields Disease Research Fields Cancer	P-glycoprotein
P-gp inhibitor 2 is a potent P-gp inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N10489

BChE-IN-12	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀ value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Bletilla striata (Thunb. ex Murray) Rchb. f. Classification of Application Fields Neurological Disease Orchidaceae Source classification Phenols Polyphenols Plants Disease Research Fields	Cholinesterase (ChE)
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-N12581

Kuwanon U	Structural Classification Flavonoids Flavonones Source classification Morus alba L. Plants Moraceae	Cholinesterase (ChE)
Kuwanon U is a potent cholinesterase inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-N0611

alpha-Boswellic acid α-Boswellic acid	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Boswellia serrata Plants Burseraceae Inflammation/Immunology Disease Research Fields	Others
alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .

HY-122381

Kyotorphin	Structural Classification Monophenols Neurological Disease Classification of Application Fields Source classification Phenols Endogenous metabolite Disease Research Fields	Bacterial Endogenous Metabolite
Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients .

HY-N4027

Hydrangenol 8-O-glucoside Hydrangenol 8-O-β-D-glucopyranoside	Structural Classification Source classification Hydrangeaceae Coumarins Phenylpropanoids Plants	Cholinesterase (ChE)
Hydrangenol 8-O-glucoside (Hydrangenol 8-O-β-D-glucopyranoside) can be isolated from Hydrangea macrophyllu. Hydrangenol 8-O-glucoside is an AChE inhibitor (IC₅₀: 22.66 μM). Hydrangenol 8-O-glucoside inhibits passive cutaneous anaphylaxis (PCA) reaction .

HY-N4268

Tenuifoliside B	Source classification Polygalaceae Phenols Polyphenols Plants Polygala tenuifolia Willd.	Others
Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound .

HY-N3383

Ligustroside Ligstroside	Monophenols Iridoids Oleaceae Ligustrum japonicum Thunb. Terpenoids Source classification Phenols Plants	Mitochondrial Metabolism
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

HY-N11641

Methyl ganoderate A acetonide	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	Cholinesterase (ChE)
Methyl ganoderate A acetonide, a lanostane triterpene, is a natural product that could be isolated from the fruiting bodies of Ganoderma lucidum. Methyl ganoderate A acetonide is a potent AChE inhibitor with an IC₅₀ value of 18.35 μM. Methyl ganoderate A acetonide can be used in research of Alzheimer’s disease (AD) .

HY-113354

Anserine 1 Publications Verification	Microorganisms Immune System Disorder Ketones, Aldehydes, Acids Source classification Disease markers Nervous System Disorder Endogenous metabolite	Endogenous Metabolite
Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-125125

Danshenxinkun D	Quinones Structural Classification Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Phenanthrenequinones	Others
Danshenxinkun D is an anti-Alzheimer's disease (AD) candidate. Danshenxinkun D can significantly reverse the expression of PSEN1 and DRD2 mRNA in H₂O₂ treated PC12 cells. Danshenxinkun D can be used in the study of anti-Alzheimer's disease product candidate [1].

HY-N10701

AChE/BChE-IN-11	Structural Classification Oleaceae Syringa oblata Lindl. Source classification Plants Saccharides Monosaccharides	Cholinesterase (ChE)
AChE/BChE-IN-11 (compound 1) is a potent is a dual AChE and BChE inhibitor with IC₅₀ values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research .

HY-N0812

Timosaponin BII Prototimosaponin A III	Structural Classification Liliaceae Neurological Disease Classification of Application Fields Source classification Anemarrhena asphodeloides Bunge Plants Inflammation/Immunology Disease Research Fields Steroids	Amyloid-β
Timosaponin BII (Prototimosaponin A III) is a steroid saponin found in the rhizomes of Anemarrhena asphodeloides. Timosaponin BII has neuronal protective, anti-inflammatory and antioxidant activities .

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Structural Classification Alkaloids Other Alkaloids Source classification Plants Amaryllidaceae	Cholinesterase (ChE) nAChR
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-116753

(-)Clausenamide	Clausena lansium (Lour.) Skeels Source classification Rutaceae Plants	Amyloid-β Tau Protein
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-107577

Gedunin	Infection Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-N0028

Forsythiaside A 1 Publications Verification	Structural Classification Classification of Application Fields Oleaceae Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plants Forsythia suspensa (Thunb.) Vahl Inflammation/Immunology Disease Research Fields	Others
Forsythiaside A is an orally active phenylethanoid glycoside isolated from the dried fruits of Forsythia suspensa. Forsythiaside A is also an inhibitor of COX-2 and has anti-inflammatory, antioxidant and neuroprotective effects. Forsythiaside A prevents neuroinflammation and apoptosis caused by Aβ_25-35 damage and may be used in Alzheimer's disease (AD) research. Forsythiaside A also activates the Nrf2/HO-1 signaling pathway and inhibits OVA-induced asthma in mice .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	Structural Classification Alkaloids Source classification Plants Amaryllidaceae	nAChR Cholinesterase (ChE)
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-N2807

Acanthoside B	Monophenols Cistanche salsa (C. A. Mey.) G. Beck Source classification Lignans Phenols Orobanchaceae Phenylpropanoids Plants	Others
Acanthoside B is a potential bioactive lignan with anti-inflammatory and anti-amnesic activities. Acanthoside B can be used for alzheimer's disease and lung inflammation research

HY-106353

Smilagenin 1 Publications Verification	Structural Classification Pelargonium hortorum Bailey Liliaceae Neurological Disease Classification of Application Fields Anemarrhena asphodeloides Bunge Plants Disease Research Fields Geraniaceae Steroids	mAChR Endogenous Metabolite
Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .

HY-155535

17β-HSD10-IN-2	Structural Classification Monophenols Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor，targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10)，a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer .

HY-N0220

Dauricine 2 Publications Verification	Structural Classification Classification of Application Fields Source classification Plants Menispermaceae Menispermum dauricum Alkaloids Monophenols other families Phenols Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Cancer	Oxidative Phosphorylation NF-κB Apoptosis
Dauricine, a bisbenzylisoquinoline alkaloid in Menispermum dauricum, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing NF-κB activation in a dose- and time-dependent manner in colon cancer .

HY-N0222

Avicularin 3 Publications Verification	Flavonols Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Disease Research Fields Inflammation/Immunology Lindera aggregata (Sims) Kosterm.	COX NF-κB PPAR ERK GLUT Apoptosis
Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities .

HY-N0749

Jatrorrhizine	Alkaloids Monophenols other families Source classification Phenols Plants Isoquinoline Alkaloids	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0740

Jatrorrhizine chloride	Alkaloids Monophenols Source classification Ranunculaceae Coptis chinensis Franch. Phenols Plants Isoquinoline Alkaloids	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0749A

Jatrorrhizine hydroxide	Alkaloids Monophenols Source classification Ranunculaceae Coptis chinensis Franch. Phenols Plants Isoquinoline Alkaloids	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-16569

Colchicine Maximum Cited Publications 29 Publications Verification	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Disease Research Fields Cancer	Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .

Species:	Human (7) Mouse (1)
Tag:	His (5) SUMO (1) Tag Free (2) Myc (1) GST (1) Flag (1) Fc (1)
Source:	HEK293 (3) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P700625

	ADI Protein, Metamycoplasma hominis (HEK293, His) Arginine deiminase; Arginine dihydrolase (AD); arcA	Others	HEK293
	ADI Proteinas, central to the ADI pathway, catalyzes the initial step in L-arginine degradation. Specifically, it converts L-arginine to carbamoyl phosphate, initiating the pathway and playing a key role in regulating the overall metabolic breakdown of L-arginine. ADI Protein, Metamycoplasma hominis (HEK293, His) is the recombinant ADI protein, expressed by HEK293, with C-10*His labeled tag. The total length of ADI Protein, Metamycoplasma hominis (HEK293, His) is 408 a.a., with molecular weight of 50 kDa.

HY-P76168

	Amyloid Precursor/Beta-APP42 Protein, Human (His-GST) Amyloid-beta precursor protein; ABPP; PN-II; A4; AD1	Human	E. coli
	There is no specific Pubmed ID mentioned in the paragraph. Amyloid Precursor/Beta-APP42 Protein, Human (His-GST) is the recombinant human-derived Amyloid Precursor/Beta-APP42 protein, expressed by E. coli , with N-His, N-GST labeled tag. The total length of Amyloid Precursor/Beta-APP42 Protein, Human (His-GST) is 42 a.a., with molecular weight of ~27-31 KDa.

HY-P702818

Cereblon Protein, Human (HEK293, Flag)

Protein cereblon; CRBN; AD-006
Human HEK293

HY-P72834

	APP/Protease Nexin-II Protein, Human (HEK293, Fc) Amyloid-beta precursor protein; APP; CVAP; PN-II; PreA4; A4; AD1	Human	HEK293
	There is no specific Pubmed ID mentioned in the paragraph. APP/Protease Nexin-II Protein, Human (HEK293, Fc) is the recombinant human-derived APP/Protease Nexin-II protein, expressed by HEK293 , with C-hFc labeled tag. The total length of APP/Protease Nexin-II Protein, Human (HEK293, Fc) is 652 a.a., with molecular weight of 150-160 kDa.

HY-P71631

	PITHD1 Protein, Human (Myc, His) PITHD1; C1orf128; AD039; HT014; PP603; PITH domain-containing protein 1	Human	E. coli
	The PITHD1 protein is a key regulator of cell dynamics, specifically promoting megakaryocyte differentiation by upregulating RUNX1 expression. It does this by activating the proximal promoter of the RUNX1 gene and enhancing the translational activity of the internal ribosome entry site (IRES) element. PITHD1 Protein, Human (Myc, His) is the recombinant human-derived PITHD1 protein, expressed by E. coli , with N-His, C-Myc labeled tag. The total length of PITHD1 Protein, Human (Myc, His) is 211 a.a., with molecular weight of ~31.6 kDa.

HY-P71644

	TRMT112 Protein, Human (His-SUMO) TRMT112; AD-001; HSPC152; HSPC170; Multifunctional methyltransferase subunit TRM112-like protein; tRNA methyltransferase 112 homolog	Human	E. coli
	TRMT112 Protein activates various methyltransferases for rRNA, tRNA, and protein modifications. Partnering with BUD23, it methylates 18S rRNA's guanine N(7). With N6AMT1/HEMK2, it catalyzes N5-methylation of ETF1 on 'Gln-185' and monomethylates 'Lys-12' of histone H4 (H4K12me1). Collaborating with ALKBH8, TRMT112 methylates 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine in specific tRNA species. With THUMPD3, it contributes to N(2)-methylguanosine formation in various tRNA substrates. TRMT112 and METTL5 methylate adenine's 6th position in 18S rRNA. Its involvement in pre-rRNA processing aids small-subunit rRNA production, and diverse interactions with BUD23, N6AMT1/HEMK2, ALKBH8, and METTL5 highlight its regulatory functions. Interactions with THUMPD3, THUMPD2, and TRMT11 underscore its intricate role in these processes. TRMT112 Protein, Human (His-SUMO) is the recombinant human-derived TRMT112 protein, expressed by E. coli, with N-His, N-SUMO labeled tag. The total length of TRMT112 Protein, Human (His-SUMO) is 125 a.a., with molecular weight of ~30.2 kDa.

HY-P70660

	SNCA Protein, Mouse Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli
	SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free. The total length of SNCA Protein, Mouse is 140 a.a., with molecular weight of ~17.0 kDa.

HY-P70577

	SNCA Protein, Human Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human is the recombinant human-derived SNCA protein, expressed by E. coli , with tag free. The total length of SNCA Protein, Human is 140 a.a., with molecular weight of ~17.0 kDa.

HY-P71327

	SNCA Protein, Human (His) Alpha-Synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag. The total length of SNCA Protein, Human (His) is 140 a.a., with molecular weight of ~18.0 kDa.

Cat. No.	Product Name	Chemical Structure

HY-13575S1

Blonanserin-d5

Blonanserin-d₅ is a deuterium labeled Blonanserin. Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic[1][2].

HY-B0579S

Cyclosporin A-d4
Cyclosporin A-d₄ is the deuterium labeled Cyclosporin A. Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM. Cyclosporin A also inhibits CD11a/CD18 ad

HY-13575S

Blonanserin-d8

Blonanserin-d₈ is a deuterium labeled Blonanserin. Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic[1][2].
HY-142193S

(-)-Erinacin A-d3

(-)-Erinacin A-d₃ is the deuterium labeled (-)-Erinacin A[1].
HY-13204S2

rel-Biperiden EP impurity A-d5

rel-Biperiden EP impurity A-d₅ is deuterium labeled Biperiden (hydrochloride).
HY-146926S

16:0 Coenzyme A-d4

16:0 Coenzyme A-d₄ is deuterium labeled 16:0 Coenzyme A.
HY-146927S

24:0 Coenzyme A-d4

24:0 Coenzyme A-d₄ is deuterium labeled 24:0 Coenzyme A.
HY-113209S

8-Iso-PGF2a-d4

8-Iso-PGF2a-d4 (8-iso Prostaglandin F2α-d4) is an active compound. 8-Iso-PGF2a-d4 can be used the internal standard .
HY-143969S

KL140061A-d4

KL140061A-d₄ is the deuterium labeled KL140061A[1].
HY-113459S

Prostaglandin F1a-d9

Prostaglandin F1a-d₉ is the deuterium labeled Prostaglandin F1a[1].
HY-B0579S1

Cyclosporin A-d3

Cyclosporin A-d₃ is the d3-labeled Cyclosporin A (HY-B0579)[1].
HY-143997S

(Rac)-Nicotine EP impurity A-d4 hydrochloride

(Rac)-Nicotine EP impurity A-d₄ (hydrochloride) is the deuterium labeled (Rac)-Nicotine EP impurity A hydrochloride[1].
HY-144221S

Tiotropium bromide EP impurity A-d6

Tiotropium bromide EP impurity A-d₆ is the deuterium labeled Tiotropium bromide EP impurity A[1].
HY-150988S

2,2'-Dichloro bisphenol A-d12

2,2'-Dichloro bisphenol A-d₁₂ is the deuterium labeled 2,2'-Dichloro bisphenol A[1].
HY-150992S

2,6-Dichloro bisphenol A-d12

2,6-Dichloro bisphenol A-d₁₂ is the deuterium labeled 2,6-Dichloro bisphenol A[1].
HY-150987S

2,2',6-Trichloro bisphenol A-d11

2,2',6-Trichloro bisphenol A-d₁₁ is the deuterium labeled 2,2',6-Trichloro bisphenol A[1].

HY-131103S

Phenylethanolamine A-d3
Phenylethanolamine A-d₃ is a deuterium labeled Phenylethanolamine A. Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process[1].

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

HY-N2392S

Kukoamine A-d8 dihydrochloride
Kukoamine A-d₈ (dihydrochloride) is deuterium labeled Kukoamine A. Kukoamine A is a natural occurring spermine derivative, acts as a potent inhibitor of trypanothione reductase (Ki, 1.8 μM), with antihypertensive activity[1].

HY-B0426AS

Olopatadine-d3 hydrochloride
Olopatadine-d₃ (hydrochloride) (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis[1][2].

HY-139951S

3-Hydroxy-3-methylglutaryl-Coenzyme A-d3 ammonium

3-Hydroxy-3-methylglutaryl-Coenzyme A-d₃ (ammonium) is the deuterium labeled 3-Hydroxy-3-methylglutaryl-Coenzyme A ammonium[1].

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].

HY-113354S

Anserine-d4

Anserine-d₄ is the deuterium labeled Anserine. Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice[1][2].

HY-18260S1

Bisphenol A-d6

Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].

HY-113354S1

Anserine-d4 hydrochloride

Anserine-d₄ hydrochloride is the deuterium labeled Anserine (HY-113354). Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

HY-18260S

Bisphenol A-d16

Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S4

Bisphenol A-d4

Bisphenol A-d₄ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S6

Bisphenol A-d14

Bisphenol A-d₁₄ is a deuterium labeled Bisphenol A (HY-18260). Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-B0976AS

Fenoterol-d6 hydrobromide
Fenoterol-d₆ (hydrobromide) (Th-1165a-d6) is the deuterium labeled Fenoterol hydrobromide. Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research[1][2].

HY-18260S3

Bisphenol A-d8

Bisphenol A-d₈ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].

HY-18260S5

Bisphenol A-d4-1

Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

Cat. No.	Product Name	Application	Reactivity

HY-P81860

Presenilin 2 Antibody (YA1605)

AD3LP; AD5; E5-1; STM-2
WB, IP Human, Mouse, Rat
HY-P82133

Phospho-Presenilin 2 (Ser330) Antibody (YA1878)

AD3LP; AD5; E5-1; STM-2
WB Human, Mouse, Rat
HY-P81977

Presenilin 1 Antibody (YA1722)

PSEN1; AD3; PS1; PSNL1; Presenilin-1; PS-1; Protein S182
WB, ICC/IF, IP Human, Mouse, Rat
HY-P82123

Phospho-Presenilin 1 (Ser310) Antibody (YA1868)

PSEN1; AD3; PS1; PSNL1; Presenilin-1; PS-1; Protein S182
WB Human

HY-P81385

Amyloid Precursor Protein Antibody (YA1130) APP; A4; AD1; Amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	IHC-P	Human

HY-P83421

Steroidogenic Factor 1 Antibody (YA3166)

AD4BP; ELP; FTZ1; FTZF1; hSF 1; NR5A1; POF7; SF1; SPGF8; SRXY3; STF1; SF-1
WB Human, Mouse, Rat

HY-P82823

Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) APP; A4; AD1; Amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II	WB, ICC/IF, IP	Human, Rat

HY-P82328

alpha Synuclein Antibody (YA2073)

SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
WB, IHC-P, IP Human, Rat

HY-P81739

Phospho-alpha Synuclein (Ser129) Antibody (YA1484) SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, ICC/IF	Human, Mouse, Rat

HY-P81760

C4A Antibody (YA1505) Acidic C4; Acidic complement C4; Basic C4; Basic complement C4; C4A; C4A2; C4A3; C4A4; C4A6; C4AD; C4B1; C4B12; C4B2; C4B3; C4BD; C4F; C4S; CPAMD2; CPAMD3	WB, IHC-P, FC	Human

Cat. No.	Product Name		Classification

HY-124614

GLP-26 1 Publications Verification		Alkynes
GLP-26 is a HBV capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC₅₀=3 nM), and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools . GLP-26 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

AD

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry